D&D Pharmatech (XKRX:347850) EV-to-EBIT : -66.77 (As of Sep. 22, 2024)

View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, D&D Pharmatech's Enterprise Value is ₩377,977 Mil. D&D Pharmatech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-5,661 Mil. Therefore, D&D Pharmatech's EV-to-EBIT for today is -66.77.

The historical rank and industry rank for D&D Pharmatech's EV-to-EBIT or its related term are showing as below:

XKRX:347850' s EV-to-EBIT Range Over the Past 10 Years
Min: -66.77 Med: 20.91 Max: 27.02
Current: -66.77

During the past 6 years, the highest EV-to-EBIT of D&D Pharmatech was 27.02. The lowest was -66.77. And the median was 20.91.

XKRX:347850's EV-to-EBIT is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 8.975 vs XKRX:347850: -66.77

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. D&D Pharmatech's Enterprise Value for the quarter that ended in Jun. 2024 was ₩285,453 Mil. D&D Pharmatech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-5,661 Mil. D&D Pharmatech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -1.98%.

D&D Pharmatech EV-to-EBIT Historical Data

The historical data trend for D&D Pharmatech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech EV-to-EBIT Chart

D&D Pharmatech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

D&D Pharmatech Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24
EV-to-EBIT	-	-	-	-	-

Competitive Comparison of D&D Pharmatech's EV-to-EBIT

For the Biotechnology subindustry, D&D Pharmatech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

D&D Pharmatech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D&D Pharmatech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where D&D Pharmatech's EV-to-EBIT falls into.

D&D Pharmatech EV-to-EBIT Calculation

D&D Pharmatech's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	377977.118	/	-5660.9
	=	-66.77

D&D Pharmatech's current Enterprise Value is ₩377,977 Mil.
D&D Pharmatech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-5,661 Mil.

D&D Pharmatech (XKRX:347850) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

D&D Pharmatech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 )	=	EBIT	/	Enterprise Value (Q: Jun. 2024 )
	=	-5660.9	/	285452.932
	=	-1.98 %

D&D Pharmatech's Enterprise Value for the quarter that ended in Jun. 2024 was ₩285,453 Mil.
D&D Pharmatech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-5,661 Mil.

D&D Pharmatech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR

Website

http://www.ddpharmatech.com

D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech Headlines

No Headlines